The United Laboratories International Holdings Limited (HKG:3933)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
12.25
-0.30 (-2.39%)
Mar 4, 2026, 4:08 PM HKT
-5.91%
Market Cap 24.17B
Revenue (ttm) 15.45B
Net Income (ttm) 3.36B
Shares Out 1.97B
EPS (ttm) 1.85
PE Ratio 6.63
Forward PE 7.53
Dividend 0.63 (5.05%)
Ex-Dividend Date Sep 25, 2025
Volume 17,323,800
Average Volume 10,541,183
Open 12.55
Previous Close 12.55
Day's Range 11.90 - 12.55
52-Week Range 11.02 - 17.98
Beta 0.11
RSI 45.08
Earnings Date Mar 26, 2026

About HKG:3933

The United Laboratories International Holdings Limited, an investment holding company, engages in the research and development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, amoxicillin... [Read more]

Sector Healthcare
Founded 1990
Employees 17,400
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3933
Full Company Profile

Financial Performance

In 2024, HKG:3933's revenue was 13.76 billion, an increase of 0.14% compared to the previous year's 13.74 billion. Earnings were 2.66 billion, a decrease of -1.54%.

Financial numbers in CNY Financial Statements

News

Novo Nordisk, United Laboratories International Announce Positive Topline Data From UBT251 Trial

(RTTNews) - Novo Nordisk A/S (NVO), along with The United Laboratories International Holdings Limited, Tuesday announced topline results from a Chinese phase 2 trial of UBT251, a drug jointly develope...

7 days ago - Nasdaq

Novo Nordisk And United Lab Reports Positive Results From Chinese Phase 2 Trial Of UBT251 In Obesity

(RTTNews) - Novo Nordisk A/S (NVO) and The United Laboratories International Holdings Limited (ULIHF, UNJ.F) on Tuesday announced topline results from a Chinese phase 2 trial evaluating UBT251, jointl...

8 days ago - Nasdaq